Neoleukin Therapeutics, Inc. Profile Avatar - Palmy Investing

Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic …

Drug Manufacturers - Specialty & Generic
US, Seattle [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Neoleukin Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of NLTX's Analysis
CIK: - CUSIP: 64049K104 ISIN: US64049K2033 LEI: - UEI: -
Secondary Listings
NLTX has no secondary listings inside our databases.